Accession Number: | 0001562180-19-001030 |
Date: | 2019-02-13 |
Issuer: | SAGE THERAPEUTICS, INC. (SAGE) |
Original Submission Date: |
CLOONAN MICHAEL
C/O SAGE THERAPEUTICS, INC.
215 FIRST STREET
CAMBRIDGE, MA 02142
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 157.63 | 2019-02-13 | deemed execution date | A | 24,500 (a) | 2029-02-13 | common stock 24,500 | $157.63 | 24,500 | direct |
ID | footnote |
---|---|
f1 | the securities awarded on february 13, 2019 were in the form of stock options issued pursuant to the sage therapeutics, inc. 2014 stock option and incentive plan. options to purchase 6,125 shares of common stock shall vest on the one year anniversary of february 13, 2019, with 18,375 shares vesting in 36 equal monthly installments thereafter. |